Lyndra Therapeutics
CEO: Jessica Ballinger
Lyndra Therapeutics, Inc., is a biotechnology company that is committed to improving healthcare outcomes by developing orally administered, ultra-long acting, sustained-release therapies. The Company’s business is currently focused on developing and commercializing therapies for the treatment of psychiatric disorders, diabetes, cardiovascular disease, Alzheimer’s Disease, HIV, transplant rejection, opioid use disorder, and malaria as well as developing a once-monthly oral contraceptive.
Currently, medication non-adherence costs more and affects more people than any single disease. Approximately half of medications for chronic disease are not taken as prescribed, and hence the U.S. suffers significant associated costs, both in terms of dollars and lives. Ultimately, Lyndra Therapeutic’s technology will be leveraged to eliminate daily pills for any oral therapy requiring multi-day treatment.